🏢 公司NewsroomRIGLCodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:05:00·⟳ 抓取 20:05:09 +9s·⚡ 决策 07-28 20:06:14 +1m05s·90.9 天前
Rigel宣布将于8月4日盘后披露2026年二季度业绩并召开电话会
本次只是公司例行预告财报披露和电话会时间，没有披露收入、利润、指引、产品进展或监管里程碑等新增经营事实。
📄 原文RIGL↗ 原文
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced t…
不做 Rigel Pharmaceuticals（RIGL.US）
例行财报发布时间和电话会预告，没有披露业绩数据、指引变化、产品进展或监管结果，无法形成同向交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是公司例行预告财报披露和电话会时间，没有披露收入、利润、指引、产品进展或监管里程碑等新增经营事实。
主要风险
- 真正可交易信息需等2026年8月4日盘后业绩和业务更新落地后重新研判。
原文全文
展开原文 · 1,787 字
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and will be accessible from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financial-results-302835770.html
SOURCE Rigel Pharmaceuticals, Inc.
Released July 28, 2026
SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and will be accessible from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financial-results-302835770.html
SOURCE Rigel Pharmaceuticals, Inc.
Released July 28, 2026
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。